Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Current Deferred Revenue (2020 - 2025)

Aligos Therapeutics filings provide 5 years of Current Deferred Revenue readings, the most recent being $168000.0 for Q3 2025.

  • On a quarterly basis, Current Deferred Revenue changed N/A to $168000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $168000.0, a N/A change, with the full-year FY2024 number at $151000.0, down 88.46% from a year prior.
  • Current Deferred Revenue hit $168000.0 in Q3 2025 for Aligos Therapeutics, down from $579000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $7.6 million in Q1 2021 to a low of $151000.0 in Q4 2024.
  • Median Current Deferred Revenue over the past 4 years was $1.3 million (2023), compared with a mean of $3.3 million.
  • The widest YoY moves for Current Deferred Revenue: up 88.46% in 2024, down 88.46% in 2024.
  • Aligos Therapeutics' Current Deferred Revenue stood at $6.6 million in 2021, then plummeted by 80.29% to $1.3 million in 2023, then tumbled by 88.46% to $151000.0 in 2024, then grew by 11.26% to $168000.0 in 2025.
  • The last three reported values for Current Deferred Revenue were $168000.0 (Q3 2025), $579000.0 (Q2 2025), and $151000.0 (Q4 2024) per Business Quant data.